-
1 Comment
Zhejiang Xinguang Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 6.0% above its 200 day moving average.
From a valuation standpoint, the stock is 19.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.8.
Zhejiang Xinguang Pharmaceutical Co., Ltd's total revenue rose by 7.7% to $84M since the same quarter in the previous year.
Its net income has increased by 18.5% to $29M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.2% to $27M since the same quarter in the previous year.
Based on the above factors, Zhejiang Xinguang Pharmaceutical Co., Ltd gets an overall score of 5/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE1000027T3 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Target Price | None |
|---|---|
| Dividend Yield | 3.0% |
| Market Cap | 2B |
| PE Ratio | 43.29 |
| Beta | 0.29 |
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of Chinese patent medicines, chemical medicines, and health food. It offers pharmaceutical products for vascular and trauma diseases, including respiratory system, digestive system, urinary system, pediatric diseases, and improving immunity. The company was incorporated in 1998 and is headquartered in Shengzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300519.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
